Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab Maintenance for Esophageal Squamous Cell Carcinoma (DESC)
NCT04054518Phase 2Unknown
- Start
- Oct 2019
- Primary completion
- Oct 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in Esophageal Squamous Cell Carcinoma (ESCC). Status: unknown.
02
Drugs
durvalumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04054518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04054518.